Transmucosal Coenzyme Q10 Composition for Mucosal Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Coenzyme Q10, despite its effectiveness, faces challenges in administration due to its oral intake difficulties for patients with serious diseases, elderly individuals, and young children, and insufficient concentration delivery to topical sites like the intestinal canal, nose, or ears, limiting its practical application.
Innovation Solution
A transmucosal administration composition containing oxidized and/or reduced coenzyme Q, absorbed through mucosal absorption, allowing for high blood concentration and effective topical delivery via formulations like suppositories, eye drops, and nose drops, with a preferred ratio of reduced coenzyme Q10 for enhanced absorption.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If oral administration is used to deliver coenzyme Q10, then the compound can be supplied to the body, but patients with serious diseases, elderly persons, and young children cannot easily intake it, and sufficient concentration cannot be obtained at topical sites
Solution Approach 1:
The invention divides the administration route into multiple segments: oral administration for systemic effects and transmucosal administration (via nose, ear, eye, or intestinal mucosa) for localized high concentration delivery. This segmentation allows different administration methods to serve different purposes, resolving the contradiction between ease of administration and concentration at topical sites.
Solution Approach 2:
The invention introduces mucosal surfaces as intermediary absorption sites between the administration site and the target tissue. By utilizing the mucosa (nose, ear, eye, or intestinal) as an intermediary, the compound can be delivered directly to topical sites with high concentration without requiring oral intake, thus resolving the contradiction.
2Device complexity
If only oxidized coenzyme Q10 is used in the composition, then the formulation is simpler, but blood concentration of coenzyme Q is lower compared to using reduced coenzyme Q
Solution Approach 1:
The invention changes the chemical state parameter of coenzyme Q by including both oxidized and reduced forms in the composition. This parameter change (oxidation state) enhances the absorption efficiency and blood concentration of coenzyme Q, while maintaining formulation simplicity through a straightforward compositional ratio specification.
3Ease of manufacture
If coenzyme Q10 is administered topically to sites like intestinal canal, nose, or ears, then localized treatment is possible, but sufficient concentration cannot be obtained due to poor absorption
Solution Approach 1:
The invention uses the mucosal surface as an intermediary that facilitates direct absorption into the underlying tissue. The mucosa acts as a gateway that enables efficient transfer of coenzyme Q from the topical application site to the target tissue, resolving the absorption problem and achieving sufficient concentration at the topical site.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The transmucosal composition effectively increases coenzyme Q10 levels in blood and mucosal tissues, overcoming oral administration limitations and providing therapeutic benefits for various diseases, particularly in elderly persons and those with topical issues.
Implementation Method 1
coenzyme Q undergoes oxidation/reduction cycles in living organisms and functions as an electron carrier in an electron transport system
Implementation Method 2
coenzyme Q can be absorbed into the body through mucosal absorption
Data Source
AI summary
The present invention relates to the supply of coenzyme Q which is highly useful in maintaining human health, and provides a method and preparations whereby coenzyme Q can be efficiently supplied to patients having difficulties in oral administration, aged having swallowing difficulties and patients with diseases caused by topical disorders. It is found that the coenzyme Q concentration in the blood or topical mucosae can be elevated by using a composition for transmucosal administration containing oxidized coenzyme Q and/or reduced coenzyme Q as the active ingredient, wherein the total content of the oxidized coenzyme Q and the reduced coenzyme Q amounts to 0.0001 to 99% by weight of the whole composition.